Diabetic Retinopathy Market Analysis Report By Type, By Management And Segment Forecasts, 2018 - 2025

  • ID: 4479737
  • Report
  • 81 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • Alimera Sciences
  • Allergan plc
  • Ampio Pharmaceuticals
  • Bayer Healthcare
  • BCN Peptides
  • Genentech
  • MORE
The global diabetic retinopathy market is anticipated to reach USD 10.08 billion by 2025. Rising prevalence of diabetes, growing geriatric population, and increasing prevalence of blindness due to diabetes are among the key factors anticipated to bolster market growth over the forecast period.

Diabetes is amongst the leading cause of blindness in people. Blindness is caused due to leaking or rupturing of retinal blood vessels, which may be permanent or temporary in nature depending on the disease-stage. According to the Department of Assistive and Rehabilitative Services (DARS), Texas, around 78.0% cases of diabetic retinopathy were reported in 2013 that may eventually lead to loss of vision. In addition, as per the Royal National Institute of Blind People (RNIB), diabetic retinopathy was amongst the leading causes of blindness in UK in 2017. Rising patient awareness levels and increasing healthcare expenditure are also among the factors which are likely to propel market growth.

Moreover, the increasing geriatric population in both developed and developing nations is expected to propel the diabetic retinopathy market over the forecast period. According to the Population Reference Bureau report titled "Aging in the United States”, the number of people in the U.S., aged 65 years and over were projected to increase from around 46 million in 2016 to over 98 million by 2060.

Further key findings from the study suggest:
  • Non-proliferative diabetic retinopathy accounted for the largest share, by type, in 2016. Presence of large number of patients within the bracket of less than 10 years of diabetic history contributed to the large size of this segment.
  • Anti-VEGF segment accounted for the largest share, by management, in 2016. High applicability of these drugs in treatment of early diagnosis and mild to moderate cases of non-proliferative DR treatment is among the prime factors leading to segmental growth.
  • Asia Pacific market is expected to grow with the highest CAGR over the forecast period. Large population base in this region, high prevalence of diabetes, and rising geriatric population are likely to bolster the market.
  • Major players of the market include Bayer Healthcare, Novartis AG, Regeneron Pharmaceuticals Inc., Allergan plc, ThromboGenics NV, Sirnaomics, Inc., Genentech, Glycadia Pharmaceuticals, Alimera Sciences, and Ampio Pharmaceuticals, BCN Peptides, and Kowa Group.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Alimera Sciences
  • Allergan plc
  • Ampio Pharmaceuticals
  • Bayer Healthcare
  • BCN Peptides
  • Genentech
  • MORE
Chapter 1 Executive Summary

Chapter 2 Research Methodology
2.1 Information Procurement
2.2 Data Analysis
2.3 Region Wise Market Calculation
2.3.1 Region Wise Market: Base Estimates
2.3.2 Global Market: CAGR Calculation
2.4 Region based segment share calculation
2.5 List of Secondary Sources (partial list)
2.6 Market Snapshot

Chapter 3 Market Variables, Trends & Scope
3.1 Market segmentation & scope
3.1.1 Market Driver Analysis
3.1.1.1 Increasing prevalence of diabetes
3.1.1.2 Growing geriatric population base
3.1.1.3 Increasing prevalence of blindness due to diabetes.
3.1.2 Market Restraint Analysis
3.1.2.1 Lack of accurate diagnosis
3.1.2.2 Side effects of treatment
3.2 Diabetic retinopathy: Epidemiology & guidelines
3.3 Diabetic retinopathy: Pipeline overview
3.4 Penetration & growth prospect mapping: Product
3.5 Diabetic retinopathy Market - SWOT Analysis, By Factor (political & legal, economic and technological)
3.6 Industry Analysis - Porter’s

Chapter 4 Diabetic Retinopathy Market: Type Estimates & Trend Analysis
4.1 Diabetic retinopathy market: type movement analysis
4.2 Proliferative diabetic retinopathy
4.2.1 Proliferative Diabetic retinopathy market, 2014 - 2025 (USD Million)
4.3 Non-proliferative diabetic retinopathy
4.3.1 Non-proliferative Diabetic retinopathy market, 2014 - 2025 (USD Million)

Chapter 5 Diabetic Retinopathy Market: Management Estimates & Trend Analysis
5.1 Diabetic retinopathy market: management movement analysis
5.2 Anti-VEGF therapy
5.3 Anti-VEGF market, 2014 - 2025 (USD Million)
5.4 Intraocular steroid injection
5.4.1 Intraocular steroid injection market, 2014 - 2025 (USD Million)
5.5 Laser surgery
5.5.1 Laser surgery market, 2014 - 2025 (USD Million)
5.6 Vitrectomy
5.6.1 Vitrectomy market, 2014 - 2025 (USD Million)

Chapter 6 Diabetic Retinopathy Market: Regional Estimates & Trend Analysis, by Type, and Management
6.1 Diabetic retinopathy market share by region, 2016 & 2025
6.2 North America
6.2.1 North America Diabetic retinopathy market, 2014 - 2025 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. Diabetic retinopathy market, 2014 - 2025 (USD Million)
6.2.3 Canada
6.2.3.1 Canada Diabetic retinopathy market, 2014 - 2025 (USD Million)
6.3 Europe
6.3.1 Europe Diabetic retinopathy market, 2014 - 2025 (USD Million)
6.3.2 UK
6.3.2.1 UK Diabetic retinopathy market, 2014 - 2025 (USD Million)
6.3.3 Germany
6.3.3.1 Germany Diabetic retinopathy market, 2014 - 2025 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Diabetic retinopathy market, 2014 - 2025 (USD Million)
6.4.2 Japan
6.4.2.1 Japan Diabetic retinopathy market, 2014 - 2025 (USD Million)
6.4.3 China
6.4.3.1 China Diabetic retinopathy market, 2014 - 2025 (USD Million)
6.5 Latin America
6.5.1 Latin America Diabetic retinopathy market, 2014 - 2025 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil Diabetic retinopathy market, 2014 - 2025 (USD Million)
6.6 MEA
6.6.1 MEA Diabetic retinopathy market market, 2014 - 2025 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa Diabetic retinopathy market, 2014 - 2025 (USD Million)

Chapter 7 Competitive Landscape
7.1 Bayer Healthcare
7.1.1 Company Overview
7.1.2 Financial Performance- Bayer Group
7.1.3 Product Benchmarking
7.1.4 Strategic Initiatives
7.2 Novartis AG
7.2.1 Company Overview
7.2.2 Financial Performance
7.2.3 Product Benchmarking
7.2.4 Strategic Initiatives
7.3 Regeneron Pharmaceuticals Inc.
7.3.1 Company Overview
7.3.2 Financial Performance
7.3.3 Product Benchmarking
7.3.4 Strategic Initiatives
7.4 Allergan plc
7.4.1 Company Overview
7.4.2 Financial Performance
7.4.3 Product Benchmarking
7.4.4 Strategic Initiatives
7.5 ThromboGenics NV
7.5.1 Company Overview
7.5.2 Financial Performance
7.5.3 Product Benchmarking
7.5.4 Strategic Initiatives
7.6 Sirnaomics, Inc.
7.6.1 Company Overview
7.6.2 Financial Performance
7.6.3 Product Benchmarking
7.7 Genentech
7.7.1 Company Overview
7.7.2 Financial Performance-Roche
7.7.3 Product Benchmarking
7.7.4 Strategic Initiatives
7.8 Glycadia Pharmaceuticals
7.8.1 Company Overview
7.8.2 Financial Performance
7.8.3 Product Benchmarking
7.9 Alimera Sciences
7.9.1 Company Overview
7.9.2 Financial Performance
7.9.3 Product Benchmarking
7.9.4 Strategic Initiatives
7.10 Ampio Pharmaceuticals
7.10.1 Company Overview
7.10.2 Financial Performance
7.10.3 Product Benchmarking
7.10.4 Strategic Initiatives
7.11 BCN Peptides
7.11.1 Company Overview
7.11.2 Financial Performance
7.11.3 Product Benchmarking
7.11.4 Strategic Initiatives
7.12 Kowa Group
7.12.1 Company Overview
7.12.2 Financial Performance
7.12.3 Product Benchmarking
7.12.4 Strategic Initiatives

List of Tables

Table 1 Global diabetic retinopathy market, by type, 2014 - 2025 (USD Million)
Table 2 Global diabetic retinopathy market, by management, 2014 - 2025 (USD Million)
Table 3 Global diabetic retinopathy market, by region, 2014 - 2025 (USD Million)
Table 4 North America diabetic retinopathy market, by region, 2014 - 2025 (USD Million)
Table 5 North America diabetic retinopathy market, by type, 2014 - 2025 (USD Million)
Table 6 North America Diabetic Retinopathy market, by management, 2014 - 2025 (USD Million)
Table 7 U.S. diabetic retinopathy market, by type, 2014 - 2025 (USD Million)
Table 8 U.S. Diabetic Retinopathy market, by management, 2014 - 2025 (USD Million)
Table 9 Canada diabetic retinopathy market, by type, 2014 - 2025 (USD Million)
Table 10 Canada diabetic retinopathy market, by management, 2014 - 2025 (USD Million)
Table 11 Europe diabetic retinopathy market, by region, 2014 - 2025 (USD Million)
Table 12 Europe diabetic retinopathy market, by type, 2014 - 2025 (USD Million)
Table 13 Europe diabetic retinopathy market, by management, 2014 - 2025 (USD Million)
Table 14 Germany diabetic retinopathy market, by type, 2014 - 2025 (USD Million)
Table 15 Germany diabetic retinopathy market, by management, 2014 - 2025 (USD Million)
Table 16 UK diabetic retinopathy market, by type, 2014 - 2025 (USD Million)
Table 17 UK diabetic retinopathy market, by management, 2014 - 2025 (USD Million)
Table 18 Asia Pacific diabetic retinopathy market, by region, 2014 - 2025 (USD Million)
Table 19 Asia Pacific diabetic retinopathy market, by type, 2014 - 2025 (USD Million)
Table 20 Asia Pacific diabetic retinopathy market, by management, 2014 - 2025 (USD Million)
Table 21 China diabetic retinopathy market, by type, 2014 - 2025 (USD Million)
Table 22 China diabetic retinopathy market, by management, 2014 - 2025 (USD Million)
Table 23 Japan diabetic retinopathy market, by type, 2014 - 2025 (USD Million)
Table 24 Japan diabetic retinopathy market, by management, 2014 - 2025 (USD Million)
Table 25 Latin America diabetic retinopathy market, by region, 2014 - 2025 (USD Million)
Table 26 Latin America diabetic retinopathy market, by type, 2014 - 2025 (USD Million)
Table 27 Latin America diabetic retinopathy market, by management, 2014 - 2025 (USD Million)
Table 28 Brazil diabetic retinopathy market, by type, 2014 - 2025 (USD Million)
Table 29 Brazil diabetic retinopathy market, by management, 2014 - 2025 (USD Million)
Table 30 MEA diabetic retinopathy market, by region, 2014 - 2025 (USD Million)
Table 31 MEA diabetic retinopathy market, by type, 2014 - 2025 (USD Million)
Table 32 MEA diabetic retinopathy market, by management, 2014 - 2025 (USD Million)
Table 33 South Africa diabetic retinopathy market, by type, 2014 - 2025 (USD Million)
Table 34 South Africa diabetic retinopathy market, by management, 2014 - 2025 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 FIG. 7 Market summary (Figures in USD Million, 2016) Million), 2016
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Diabetes prevalence of top 10 countries in 2013 in the age group of 20 to 79 years (million)
FIG. 12 Current and projected prevalence of diabetes, by geography, 2013 & 2035 (% increase)
FIG. 13 Growth in diabetic retinopathy cases according to age and gender (%)
FIG. 14 Market restraint relevance analysis (Current & future impact)
FIG. 15 Penetration & growth prospect mapping
FIG. 16 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 17 Porter’s Five Forces Analysis
FIG. 18 Diabetic retinopathy market, type outlook key takeaways
FIG. 19 Diabetic retinopathy market: type movement analysis
FIG. 20 Proliferative Diabetic retinopathy market, 2014 - 2025 (USD Million)
FIG. 21 Non-proliferative Diabetic retinopathy market, 2014 - 2025 (USD Million)
FIG. 22 Diabetic retinopathy market, management outlook key takeaways
FIG. 23 Diabetic retinopathy market: management movement analysis
FIG. 24 Anti-VEGF market, 2014 - 2025 (USD Million)
FIG. 25 Intraocular steroid injection market, 2014 - 2025 (USD Million)
FIG. 26 Laser surgery market, 2014 - 2025 (USD Million)
FIG. 27 Vitrectomy market, 2014 - 2025 (USD Million)
FIG. 28 Regional market place: Key takeaways
FIG. 29 Regional outlook, 2016 & 2025
FIG. 30 North America Diabetic retinopathy market, 2014 - 2025 (USD Million)
FIG. 31 U.S. Diabetic retinopathy market, 2014 - 2025 (USD Million)
FIG. 32 Canada Diabetic retinopathy market, 2014 - 2025 (USD Million)
FIG. 33 Europe Diabetic retinopathy market, 2014 - 2025 (USD Million)
FIG. 34 UK Diabetic retinopathy market, 2014 - 2025 (USD Million)
FIG. 35 Germany Diabetic retinopathy market, 2014 - 2025 (USD Million)
FIG. 36 Asia Pacific Diabetic retinopathy market, 2014 - 2025 (USD Million)
FIG. 37 Japan Diabetic retinopathy market, 2014 - 2025 (USD Million)
FIG. 38 China Diabetic retinopathy market, 2014 - 2025 (USD Million)
FIG. 39 Latin America Diabetic retinopathy market, 2014 - 2025 (USD Million)
FIG. 40 Brazil Diabetic retinopathy market, 2014 - 2025 (USD Million)
FIG. 41 MEA Diabetic retinopathy market, 2014 - 2025 (USD Million)
FIG. 42 South Africa Diabetic retinopathy market, 2014 - 2025 (USD Million)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Bayer Healthcare
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.
  • Allergan plc
  • ThromboGenics NV
  • Sirnaomics, Inc.
  • Genentech
  • Glycadia Pharmaceuticals
  • Alimera Sciences
  • Ampio Pharmaceuticals
  • BCN Peptides
  • Kowa Group
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll